Share

November 11, 2014; 83 (20) Article

The neurologic significance of celiac disease biomarkers

Andrew McKeon, Vanda A. Lennon, Sean J. Pittock, Thomas J. Kryzer, Joseph Murray
First published September 26, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000970
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1205

Share

Article Information

vol. 83 no. 20 1789-1796
DOI: 
https://doi.org/10.1212/WNL.0000000000000970
PubMed: 
25261501
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 11, 2014
  • Accepted in final form July 15, 2014
  • First Published September 26, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Andrew McKeon, MD,
    2. Vanda A. Lennon, MD, PhD,
    3. Sean J. Pittock, MD,
    4. Thomas J. Kryzer, MS and
    5. Joseph Murray, MD
  1. Andrew McKeon, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Medimmune, Inc

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Vanda A. Lennon, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Lennon and Mayo Clinic have a financial interest in the following intellectual property: “Marker for Neuromyelitis Optica.” A patent has been issued for this technology, and it has been licensed to commercial entities. They have received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies. The author receives no royalties from the sale of these tests by Mayo Medical Laboratories; however, Mayo Collaborative Services, Inc. does receive revenue for conducting these tests.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. Dr. Lennon is Director of the Mayo Neuroimmunology Laboratory that performs service testing for aquaporin-4 autoantibodies on behalf of Mayo Collaborative Service Inc., an agency of Mayo Foundation. Neither Dr. Lennon nor her laboratory benefit financially from this testing.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01-NS065829,�CNS Demyelinating Autoimmunity Targeting Water Channel Complexes�. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. “Marker for Neuromyelitis Optica”. A patent has been issued to Mayo Foundation for this technology, and it has been licensed to RSR/Kronus. Dr. Lennon has received cumulative royalties of greater than the federal threshold for significant financial interest from the licensing of these technologies.

    Royalty Payments, Technology or Inventions:

    1. Dr. Lennon has a potential financial interest in the technologies listed below: “Marker for Neuromyelitis Optica”.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sean J. Pittock, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Pittock and Mayo Clinic have a financial interest in patents (#12/678,350 filed 2010 and #12/573,942 filed 2008) that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker;

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pittock has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Pittock has received a research grant from Alexion pharmaceuticals for his investigator-initiated study entitled

    Research Support, Government Entities:

    1. RO1 NS065829-01

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation grant for NMO research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Thomas J. Kryzer, MS and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Joseph Murray, MD
    6. Scientific Advisory Boards:

    1. Alvine Bioline Rx AMAG inc Enterra health Sonomaceuticals Inc Propel inc

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. American Journal of Gastroenterology: senior associate editor, 2008- current

    Patents:

    1. A commensal as a treatment for immune disorders ( pending) US Patent No. 7,803195 titled �Obesity Treatment and Device

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. ImmunosanT Ferring inc Ironwood GSK inc

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Alba therpeutics Alvine inc Biocard

    Research Support, Government Entities:

    1. CDC , 200-2013-M-56544-1, PI 2009-present NCI, P30CA 15803-39 ( supplement) Diasio R), PI 2013-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Juvenile Diabetes Research Foundation International Bill and Malinda Gates Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Laboratory Medicine and Pathology (A.M., V.A.L., S.J.P., T.J.K.), Neurology (A.M., V.A.L., S.J.P.), Immunology (V.A.L., J.M.), and Gastroenterology (J.M.), College of Medicine, Mayo Clinic, Rochester, MN.
  1. Correspondence to Dr. McKeon: mckeon.andrew{at}mayo.edu
View Full Text

Article usage

Article usage: September 2014 to July 2022

AbstractFullPdfSource
Sep 2014307020Highwire
Oct 20144046186Highwire
Nov 2014222979147Highwire
Dec 20146132646Highwire
Jan 20152561823Highwire
Feb 20151112116Highwire
Mar 20151231522Highwire
Apr 20159056Highwire
May 2015841414Highwire
Jun 201549107Highwire
Jul 20154378Highwire
Aug 20154175Highwire
Sep 20154044Highwire
Oct 20154397Highwire
Nov 20155568Highwire
Nov 201502017pmc
Dec 20155833Highwire
Dec 201502615pmc
Jan 20164235Highwire
Jan 201603727pmc
Feb 20165076Highwire
Feb 201603625pmc
Mar 20163864Highwire
Mar 201603517pmc
Apr 201629911Highwire
Apr 201603422pmc
May 20168105Highwire
May 201603118pmc
Jun 20164722Highwire
Jun 201602012pmc
Jul 20163331Highwire
Jul 201602315pmc
Aug 20163825Highwire
Aug 201601810pmc
Sep 20164123Highwire
Sep 201603722pmc
Oct 20162711Highwire
Oct 201601614pmc
Nov 20164843Highwire
Nov 201604019pmc
Dec 20164110Highwire
Dec 201603112pmc
Jan 20174401Highwire
Jan 201702014pmc
Feb 20172833Highwire
Feb 201703320pmc
Mar 20174631Highwire
Mar 201703819pmc
Apr 20172842Highwire
Apr 2017142122pmc
May 20175211Highwire
May 2017132427pmc
Jun 20175901Highwire
Jun 2017172323pmc
Jul 20172212Highwire
Jul 201792223pmc
Aug 20172010Highwire
Aug 201792123pmc
Sep 20171223Highwire
Sep 2017133135pmc
Oct 20173057Highwire
Oct 201772324pmc
Nov 20171700Highwire
Nov 2017132829pmc
Dec 20173042Highwire
Jan 20184312Highwire
Feb 20181652Highwire
Mar 20182821Highwire
Apr 20182822Highwire
Apr 2018102426pmc
May 20182842Highwire
Jun 20183222Highwire
Jun 201882932pmc
Jul 20183211Highwire
Aug 20182912Highwire
Aug 2018143238pmc
Sep 20181811Highwire
Oct 20184300Highwire
Nov 20183543Highwire
Dec 20181541Highwire
Jan 20191642Highwire
Feb 20191822Highwire
Mar 20193043Highwire
Apr 20192300Highwire
May 20193011Highwire
Jun 20192622Highwire
Jul 20191913Highwire
Aug 20191002Highwire
Sep 20191300Highwire
Oct 20192820Highwire
Nov 20192321Highwire
Dec 20192313Highwire
Jan 20201920Highwire
Feb 20202113Highwire
Mar 20201420Highwire
Apr 20201103Highwire
May 20201812Highwire
Jun 20202432Highwire
Jul 20201521Highwire
Aug 20202301Highwire
Sep 20202023Highwire
Oct 20202614Highwire
Nov 20202231Highwire
Dec 20203101Highwire
Jan 20212949Highwire
Feb 20212731Highwire
Mar 20212610Highwire
Apr 20213926Highwire
May 20213221Highwire
Jun 20217312Highwire
Jul 20214555Highwire
Aug 20213201Highwire
Sep 20212743Highwire
Oct 20217012Highwire
Nov 20212901Highwire
Dec 20212502Highwire
Jan 20222510Highwire
Feb 20224312Highwire
Mar 20225114Highwire
Apr 20223017Highwire
May 20224626Highwire
Jun 20223421Highwire
Jul 20223202Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me